Blindness News and Research

RSS

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD Pharmaceuticals, Inc. today announced, for the first time, data from its Phase 2 trial of Iclusig (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST).

2 Jun 2014

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

FibroGen, Inc. today announced results from a Phase 2 open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and erlotinib for the treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

31 May 2014

Regular grape consumption may play role in eye health

New research presented this week at the Association for Research in Vision and Ophthalmology conference in Orlando, Florida suggests that regular grape consumption may play a role in eye health by protecting the retina from deterioration.

30 May 2014

Study shows high BP drugs may raise likelihood of age-related macular degeneration

There may be a connection between taking vasodilators and developing early-stage age-related macular degeneration (AMD), the leading cause of vision loss and blindness among Americans who are age 65 and older, according to a study published online in Ophthalmology, the journal of the American Academy of Ophthalmology.

29 May 2014

Researchers working in Palestine and Jordan to help better provision of eye care

An Aston University academic is working in Palestine and Jordan to help better the provision of eye care in the two countries as part of a €565,000 worldwide two-year project.

29 May 2014

Simple tips to keep summer injury-free

Trauma and injury remains a devastating problem in the U.S. It is the leading cause of death for those under the age of 45.

23 May 2014

Researchers discover atypical type of retina cell that plays more critical role in vision

A type of retina cell plays a more critical role in vision than previously known, a team led by Johns Hopkins University researchers has discovered.

22 May 2014

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie announced today that the U.S. Food and Drug Administration has granted HUMIRA orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye.

21 May 2014

Cigarette smoking and male sex are independent risk factors for ocular sarcoidosis

Cigarette smoking and male sex are significant risk factors for developing ocular sarcoidosis, according to a new study presented at the 2014 American Thoracic Society International Conference.

21 May 2014

CINVESTAV creates stereoscopic vision lenses for blind to navigate more easily

Combining computational geometry, artificial intelligence, geo and ultrasound techniques, among others, scientists from the Center for Research and Advanced Studies (CINVESTAV) created a device to help people with low vision or blindness to navigate more easily.

20 May 2014

Shire intends to submit NDA for lifitegrast to treat dry eye disease

Following a May 15, 2014, meeting with the U.S. Food and Drug Administration (FDA), Shire plc, the global specialty biopharmaceutical company, announces today that it intends to submit a New Drug Application for lifitegrast as a treatment for the signs and symptoms of dry eye disease in adults in the first-quarter 2015, as we complete remaining chemistry and manufacturing work.

19 May 2014

FibroGen’s Phase 2a study supports safety and efficacy of FG-3019 in IPF patients

FibroGen, Inc. (FibroGen) announced today the presentation of clinical data at the American Thoracic Society (ATS) International Conference supporting the safety and efficacy of FG-3019 in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and life-threatening lung disease for which there is currently no approved therapy in the United States.

19 May 2014

Amakem commences Phase 2 dose-ranging study of AMA0076 drug for treatment of glaucoma

Amakem Therapeutics, a clinical stage ophthalmology company, today announced that first patients have commenced treatment in a Phase 2 dose-ranging study of its lead drug candidate, AMA0076 for the treatment of glaucoma.

13 May 2014

Study reveals 70% of patients with diabetic retinopathy will develop macular edema

In Mexico, at least 14 million people have developed macular edema due to diabetes (DME), which like retinopathy affects central vision and can lead to blindness if not treated early .

13 May 2014

Scientists develop non-invasive technique to determine gene carriers for retinitis pigmentosa

Scientists have developed a non-invasive technique to determine if individuals carry a gene for an inherited eye disease known as retinitis pigmentosa.

9 May 2014

Eli and Edythe Broad Foundation gift $4 million to support UCLA research

Two new gifts from The Eli and Edythe Broad Foundation to UCLA totaling $4 million will fund research in stem cell science and digestive diseases and support the recruitment of key faculty at two renowned research centers.

9 May 2014

Janssen expands collaboration with IPM for development of dapivirine to prevent HIV

Janssen R&D Ireland Ltd. (Janssen) today announced that it has expanded its collaboration with the International Partnership for Microbicides (IPM) for the development and delivery of dapivirine (TMC120) for the prevention of HIV.

8 May 2014

Scientists develop gel based eye fluid to help stabilize eye after retinal detachment surgery

In an effort to avoid serious side effects suffered after surgery to repair retinal detachment, vision scientists have developed a new product to help stabilize the eye while it heals.

7 May 2014

People suffering from vision loss are twice as likely to suffer from depression

People suffering from vision loss are twice as likely to suffer from depression as the general population. And many psychiatric medications can cause vision problems over time.

6 May 2014

BrightFocus Foundation honors 5 outstanding scientists in fields of macular degeneration, glaucoma

The BrightFocus Foundation today honored five outstanding scientists in the fields of macular degeneration and glaucoma, presenting them with named research awards at an event during the annual meeting of the Association for Research in Vision and Ophthalmology.